LABU241122C92000
- 0.00
- 0.000.00%
Direxion Daily S&P Biotech Bull 3x Shares ETF Newsroom
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Dyne, Avidity Initiated at Outperform by RBC on DM1 Drugs
How Is The Market Feeling About United Therapeutics?
Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages
Guardant Health Shares Are Trading Higher After a Jury Issued a Decision in the Company's Favor Regarding a False Advertising Case Filed by Natera Concerning Statements Made About Guardant's Reveal Test.
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Vertex Leads J.P. Morgan's Top Biotech Picks List for 2025
Gilead Acquires Investigational HIV Vaccine From Spanish Biotech Aelix
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
Looking Into Vertex Pharmaceuticals's Recent Short Interest
Incyte To Present Late-Breaking Tafasitamab Data In Follicular Lymphoma At ASH 2024 Alongside 20 Oncology Portfolio Updates, Including Phase 3 InMIND Results And Virtual Analyst Event On December 12
Price Over Earnings Overview: Gilead Sciences
Pfizer Meets Amyloidosis Rival as BridgeBio Wins FDA Nod for Attruby
Trump Picks Surgeon Makary to Head FDA, Rep. Dave Weldon to Lead CDC
3 'Buy' Stocks and 2 'Hold' Stocks According to Oppenheimer
Demystifying Insmed: Insights From 7 Analyst Reviews
Insmed Analyst Ratings
Optimism Over Global Healthcare Sector Rises: Jefferies
Gilead Sciences Analyst Ratings
Following the US Secretary of Health, Trump's nomination for the FDA Commissioner seems to be another anti-vaccine advocate.
Makari is a surgeon who opposes overtreatment, advocates for re-evaluating hormone replacement therapy, and reducing the overuse of antibiotics.